Pemetinib indications, dosage, and contraindications

Pemigatinib is a selective FGFR (fibroblast growth factor receptor) inhibitor, mainly used to treat patients with cholangiocarcinoma carrying FGFR2 fusions or rearrangements, especially for advanced or unresectable cholangiocarcinoma that has failed first-line treatment, Pemigatinib can be used as a second-line treatment option. In addition, studies have shown that the drug may also have certain efficacy in some other solid tumors carrying FGFR mutations, but the main approved indication is still cholangiocarcinoma. Patients usually need to undergo genetic testing before use to confirm whether they carry FGFR2 fusion or rearrangement mutations to ensure the suitability of the drug.

In terms of usage and dosage, the usually recommended dose of pemetinib is 13.5 mg once a day, taken continuously for 14 days and then stopped for 7 days, that is, 21 days is a treatment cycle. The dosage and administration are based on clinical trial data and help reduce the occurrence of side effects. If the patient experiences serious adverse reactions during treatment, the dose may need to be adjusted or the medication may be suspended. The specific circumstances must be decided under the guidance of a physician. At the same time, because pemetinib may affect renal function and electrolyte balance, patients need to regularly monitor blood indicators during treatment to ensure the safety and effectiveness of the drug.

Although pemetinib has significant efficacy in some patients with cholangiocarcinoma, not all people are suitable for use. This drug should be used with caution or prohibited by the following groups: pregnant women and lactating women, as pemetinib may cause potential harm to the fetus or infant; patients with severe liver function or renal insufficiency, as the drug is mainly metabolized by the liver and excreted by the kidneys, and those with impaired function may increase the risk of drug accumulation; those who are allergic to pemetinib or its components need to avoid use. In addition, pemetinib may affect phosphate metabolism and cause hyperphosphatemia. Therefore, patients with hyperphosphatemia or metabolic abnormalities should also use it with caution under the guidance of a doctor.

During the use of pemetinib, patients need to pay attention to possible adverse reactions, such as hyperphosphatemia, fatigue, diarrhea, dry skin, stomatitis, etc. Among them, hyperphosphatemia is one of the most common adverse reactions, and patients may need to manage it through diet control or the use of phosphate-lowering drugs. In addition, pemetinib may cause ocular toxicities such as blurred vision or retinopathy, so patients are advised to undergo regular eye examinations. In general, pemetinib, as a targeted drug, provides a new option in the treatment of cholangiocarcinoma, but patients still need to use it under the guidance of a doctor and pay close attention to their own health status to ensure the safety and effectiveness of the treatment.

Reference materials:https://go.drugbank.com/drugs/DB15102